WE ARE TARGETING PAIN AT ITS SOURCE
Our novel drug compounds, improved drug-delivery systems, and drug-releasing technologies are focused on advancing pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from postoperative pain to the treatment of acute and chronic pain, including pain associated with cancer.
Topical metered-dose spray
VIRPAX has licensed a patented metered-dose spray system that delivers active pharmaceutical ingredients (API). This proprietary spray formulation delivers the API as a film and may lead to adhesion capabilities superior to those of transdermal patches, while maintaining comparable skin absorption capabilities to transdermal patches currently on the market.
CONVENIENT
No messy cream or gels that can be rubbed off by clothing or physical contact
AESTHETICALLY APPEALING
Invisible once applied
EASILY OPTIMIZABLE
Use with metered-dose delivery valves
“I feel that a large number of pain patients will prefer the spray over patches and ointment and am really glad to see this new technology that will allow more precise application while using lesser active ingredient.”
SANJAY GUPTA
President, American Pain Association
Liposomal in Hydrogel encapsulation
Our patented liposomal gel encapsulates a high dose of local anesthetic in hydrogel, cholesterol, and other “GRAS” lipids. A single dose can be injected at the surgical site to provide a prolonged postoperative analgesia effect for up to 96 hours. This may enhance recovery protocols, reduce the length of a patient’s hospital stay post-surgery, and significantly reduce or eliminate the use of opioids.
PROLONGED EFFECTS
Postoperative analgesia effect for up to 96 hours
EFFICIENT DRUG-DELIVERY
Improved onset of action and peak analgesic activity in post-operative setting
IMPROVED QUALITY OF CARE
Reduce reliance on opioid pain management; may lead to experience better rehabilitation outcomes
Enkephalin Intranasal spray
Using Molecular Envelope Technology (MET), we are working to enhance enkephalin transport to the brain through an intranasal formulation. This nanotechnology enables metabolically labile peptide molecules, like enkephalin, to pass through the blood-brain barrier in order to help manage acute and chronic pain, including pain associated with cancer. These enkephalin-filled nanoparticles are preloaded into a cartridge with compressed inert gas as a single dose that is compatible with our specialized device. With a simple press of a button, the device releases this powder as a long and thin plume penetrating the olfactory region.
DRUG LOADED NANOPARTICLES
The enkephalin molecule is loaded in nanoparticles
EASY-TO-USE DEVICE
No breath coordination required. Caregiver can administer to an incapacitated person
BLOOD-BRAIN BARRIER BYPASS
Drug bypasses the blood brain barrier by targeting the olfactory region
TARGET MARKET
Transdermal and topical non-opioid pain market
DELIVERY SYSTEM
Metered-dose spray film
Image is for illustration purposes only
BENEFITS
- Improved drying, less messy, and better skin absorption
- Better adhesiveness with direct skin contact
- Better accessibility to active joints: wrists, ankles, knees and elbows
- Improved patient compliance that could result in enhanced therapeutic outcomes
NEW DRUG APPLICATION (NDA)
As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue an accelerated 505(b)(2) New Drug Application for Epoladerm.
*We are also developing Epoladerm for a second indication, OSF200, which utilizes the same transdermal delivery system as Epoladerm, as a twice daily topical treatment for chronic osteoarthritis of the knee. OSF200 development plan is pending the approval of Epoladerm.
Probudur™
Injectable long-acting bupivacaine liposomal-gel
CAPITAL FUNDING
Probudur™
Injectable long-acting bupivacaine hydrogel
CAPITAL FUNDING
TARGET MARKET
Local anesthetic post-surgical market
DELIVERY SYSTEM
Liposomal in hydrogel encapsulation
BENEFITS
- Single dose infiltration into the surgical site
- Prolonged postoperative analgesia effect up to 96 hours
- May eliminate the need for opioids and catheters after surgery
- May reduce associated costs and length of patient stay
NEW DRUG APPLICATION (NDA)
As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue an accelerated 505(b)(2) New Drug Application for Probudur.
TARGET MARKET
In analgesics market
DELIVERY SYSTEM
Endogenous enkephalin intranasal spray
BENEFITS
- Enkephalin pro-drug formulation that targets delta receptors instead of mu receptors that are responsible for the majority of undesirable side effects associated with narcotics
- Analgesic potential to manage acute and chronic pain, including pain associated with cancer, without the concerns of opioid tolerance, withdrawal, respiratory depression, or euphoria
MECHANISM OF ACTION
Brain delivery: Molecular Envelope Technology (MET) allows for highly stable nanoparticles to wrap around and encapsulate hydrophobic drugs and peptides, creating a protective molecular “envelope.” MET allows for increased bioavailability of drugs that would otherwise be rapidly degraded. In the case of intranasally administered Envelta™, MET increases dwell time in the nares promoting delivery via the olfactory route across the blood brain barrier and into the central nervous system. Here they target the delta opioid receptors, promoting analgesia (pain relief) without characteristic mu opioid related side-effects.
*We are also developing Envelta™ for a second indication, PES200, which utilizes the same delivery mechanism and active as Envelta™. PES200 enables the delivery of a metabolically labile peptide drug (enkephalin) into the brain for post-traumatic stress disorder. PES200 development plan is pending a grant approval.
Further, we recently entered into a Collaboration and License Agreement with Nanomerics Ltd. for the exclusive North American license to develop and commercialize a High-Density Molecular Masking Spray (“MMS019”) as an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans. We plan to develop MMS019 primarily through grants.
